Overview

An Open-Label Pilot Study of Sublocade as Treatment for Opiate Use Disorder

Status:
Completed
Trial end date:
2020-02-28
Target enrollment:
Participant gender:
Summary
The proposed study is a 12-week, open-label pilot study of sublocade (extended-release burprenorphine, BXR) as treatment for opiate use disorder (OUD) testing positive for Highly Potent Synthetic Opioids (HPSO). The investigators plan to enroll 10 participants into the study.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
New York State Psychiatric Institute
Treatments:
Buprenorphine